KBC Group’s Viridian Therapeutics VRDN Stock Holding History

KBC Group’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$85K	Hold	4,120	–	–	﹤0.01%	1490
2026 Q2	$76K	Buy	4,120 +2,383	+137%	+$38.4K	﹤0.01%	1554
2026 Q1	$34K	Buy	+1,737	New	+$51.6K	﹤0.01%	1773

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

KBC Group's VRDN Position: Q3 2026 in Review

KBC Group held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 4,120 shares worth $85K. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

KBC Group first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

KBC Group held 4,120 shares of Viridian Therapeutics worth $85K as of Q3 2026.
KBC Group left its Viridian Therapeutics share count unchanged in Q3 2026.
Viridian Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1490 holding.
KBC Group first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.